Vigil Neuroscience (NASDAQ:VIGL) Downgraded by William Blair to Hold

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) was downgraded by analysts at William Blair from a "strong-buy" rating to a "hold" rating in a report released on Thursday, MarketBeat Ratings reports. William Blair also issued estimates for Vigil Neuroscience's FY2027 earnings at ($1.78) EPS.

VIGL has been the subject of a number of other research reports. HC Wainwright cut their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Wedbush reaffirmed an "outperform" rating and issued a $13.00 price target on shares of Vigil Neuroscience in a research note on Monday, May 5th. Finally, Guggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $13.00.

Vigil Neuroscience Trading Up 241.1%

Shares of Vigil Neuroscience stock opened at $7.88 on Thursday. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $7.95. The company has a market cap of $367.78 million, a P/E ratio of -3.83 and a beta of 1.90. The stock has a 50-day moving average price of $2.07 and a 200 day moving average price of $2.27.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. On average, equities analysts forecast that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

A number of hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC lifted its stake in Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Vigil Neuroscience during the 4th quarter worth $83,000. Barclays PLC raised its holdings in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in shares of Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock valued at $117,000 after purchasing an additional 49,000 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.